RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation

NASDAQ:RIGL • US7665597024

Current stock price

32.29 USD
-0.2 (-0.62%)
Last:

This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. RIGL Profitability Analysis

1.1 Basic Checks

  • RIGL had positive earnings in the past year.
  • RIGL had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: RIGL reported negative net income in multiple years.
  • In multiple years RIGL reported negative operating cash flow during the last 5 years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • The Return On Assets of RIGL (71.46%) is better than 99.42% of its industry peers.
  • RIGL has a Return On Equity of 93.75%. This is amongst the best in the industry. RIGL outperforms 99.42% of its industry peers.
  • The Return On Invested Capital of RIGL (23.92%) is better than 97.87% of its industry peers.
Industry RankSector Rank
ROA 71.46%
ROE 93.75%
ROIC 23.92%
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400

1.3 Margins

  • With an excellent Profit Margin value of 124.72%, RIGL belongs to the best of the industry, outperforming 98.64% of the companies in the same industry.
  • RIGL's Operating Margin of 42.63% is amongst the best of the industry. RIGL outperforms 98.26% of its industry peers.
  • RIGL has a Gross Margin of 93.33%. This is amongst the best in the industry. RIGL outperforms 93.99% of its industry peers.
  • RIGL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 42.63%
PM (TTM) 124.72%
GM 93.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RIGL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RIGL is creating value.
  • The number of shares outstanding for RIGL has been increased compared to 1 year ago.
  • RIGL has less shares outstanding than it did 5 years ago.
  • RIGL has a better debt/assets ratio than last year.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 1.87 indicates that RIGL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • RIGL has a Altman-Z score of 1.87. This is in the better half of the industry: RIGL outperforms 64.53% of its industry peers.
  • The Debt to FCF ratio of RIGL is 0.69, which is an excellent value as it means it would take RIGL, only 0.69 years of fcf income to pay off all of its debts.
  • RIGL has a better Debt to FCF ratio (0.69) than 95.16% of its industry peers.
  • RIGL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RIGL (0.06) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.69
Altman-Z 1.87
ROIC/WACC2.43
WACC9.86%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.42 indicates that RIGL has no problem at all paying its short term obligations.
  • The Current ratio of RIGL (2.42) is worse than 72.09% of its industry peers.
  • A Quick Ratio of 2.30 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL's Quick ratio of 2.30 is on the low side compared to the rest of the industry. RIGL is outperformed by 71.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.3
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RIGL Growth Analysis

3.1 Past

  • RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 593.62%, which is quite impressive.
  • RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.15%.
  • Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 22.06% on average per year.
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%

3.2 Future

  • Based on estimates for the next years, RIGL will show a decrease in Earnings Per Share. The EPS will decrease by -2.44% on average per year.
  • The Revenue is expected to grow by 6.25% on average over the next years.
EPS Next Y-35.44%
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
EPS Next 5Y-2.44%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

8

4. RIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 4.95, which indicates a rather cheap valuation of RIGL.
  • RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.64% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of RIGL to the average of the S&P500 Index (27.95), we can say RIGL is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 7.67, the valuation of RIGL can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.45% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of RIGL to the average of the S&P500 Index (38.68), we can say RIGL is valued rather cheaply.
Industry RankSector Rank
PE 4.95
Fwd PE 7.67
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaply inside the industry as 98.84% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, RIGL is valued cheaply inside the industry as 98.45% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.89
EV/EBITDA 3
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • RIGL has a very decent profitability rating, which may justify a higher PE ratio.
  • RIGL's earnings are expected to decrease with -16.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RIGL Dividend Analysis

5.1 Amount

  • No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RIGL Fundamentals: All Metrics, Ratios and Statistics

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (4/21/2026, 3:50:00 PM)

32.29

-0.2 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners90.16%
Inst Owner Change0.01%
Ins Owners2.98%
Ins Owner Change6.76%
Market Cap596.72M
Revenue(TTM)294.28M
Net Income(TTM)367.02M
Analysts80
Price Target52.22 (61.72%)
Short Float %21.28%
Short Ratio10.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.95%
Min EPS beat(2)-9.57%
Max EPS beat(2)67.46%
EPS beat(4)3
Avg EPS beat(4)168.74%
Min EPS beat(4)-9.57%
Max EPS beat(4)592.43%
EPS beat(8)6
Avg EPS beat(8)228.66%
EPS beat(12)10
Avg EPS beat(12)171.43%
EPS beat(16)13
Avg EPS beat(16)137.97%
Revenue beat(2)1
Avg Revenue beat(2)4.83%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)10.05%
Revenue beat(4)3
Avg Revenue beat(4)10.23%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)19.17%
Revenue beat(8)6
Avg Revenue beat(8)10%
Revenue beat(12)10
Avg Revenue beat(12)7.75%
Revenue beat(16)12
Avg Revenue beat(16)11.69%
PT rev (1m)8.94%
PT rev (3m)9.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.35%
EPS NY rev (1m)1.64%
EPS NY rev (3m)-4.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.56%
Valuation
Industry RankSector Rank
PE 4.95
Fwd PE 7.67
P/S 2.03
P/FCF 7.89
P/OCF 7.89
P/B 1.52
P/tB 1.63
EV/EBITDA 3
EPS(TTM)6.52
EY20.19%
EPS(NY)4.21
Fwd EY13.04%
FCF(TTM)4.09
FCFY12.68%
OCF(TTM)4.09
OCFY12.68%
SpS15.92
BVpS21.18
TBVpS19.84
PEG (NY)N/A
PEG (5Y)N/A
Graham Number55.7467 (72.64%)
Profitability
Industry RankSector Rank
ROA 71.46%
ROE 93.75%
ROCE 30.28%
ROIC 23.92%
ROICexc 38.21%
ROICexgc 42.24%
OM 42.63%
PM (TTM) 124.72%
GM 93.33%
FCFM 25.71%
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.69
Debt/EBITDA 0.18
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage 19.09
Cash Conversion 59.16%
Profit Quality 20.61%
Current Ratio 2.42
Quick Ratio 2.3
Altman-Z 1.87
F-Score6
WACC9.86%
ROIC/WACC2.43
Cap/Depr(3y)409.8%
Cap/Depr(5y)265.74%
Cap/Sales(3y)4.35%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-35.44%
EPS Next 2Y-24.19%
EPS Next 3Y-16.16%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
EBIT growth 1Y418.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.48%
EBIT Next 3Y9.38%
EBIT Next 5YN/A
FCF growth 1Y143.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.4%
OCF growth 3YN/A
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


What is the profitability of RIGL stock?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


Can you provide the financial health for RIGL stock?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.


What is the earnings growth outlook for RIGEL PHARMACEUTICALS INC?

The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to decline by -35.44% in the next year.